Otsuka and Proteus Digital Health Expands Collaboration to Advance Smart Pills for Mental Health

Otsuka proteus collaboration

Otsuka Pharmaceutical Co., Ltd. and Proteus Digital Health has agreed to expand global collaboration for the further development and commercialization of a portfolio of medicines including the FDA-approved ABILIFY MYCITE® (aripiprazole tablets with sensor).

Read more Otsuka Collaborates with Magellan Health to Bring the Abilify MyCite Drug-Device Combo to the US Market

As part of the expanded collaboration, Otsuka made $88 million in related equity and other payments to Proteus. The expanded agreement covers the development and commercialization of digital medicines over the next five years, said a press release.

“We are pleased to continue to focus on opportunities to further integrate digital medicines into healthcare eco-systems to provide value-added outcomes for patients suffering from unmet medical needs in the mental health field,” stated Kabir Nath, President and CEO, Otsuka North America Pharmaceutical Business Division, Otsuka America, Inc. “Our expanding collaboration with Proteus is a cornerstone of this strategy, and further enables us to serve the mental health community by developing additional innovative technology solutions.”

Otsuka proteus collaboration

A team of researchers from both Otsuka and Proteus will work together for the commercial development and market coordination of the ABILIFY MYCITE System, software integration and standardization, manufacturing and supply chain integration, and coordination. This includes the joint development of an expanded portfolio of digital medicines consisting of other therapies such as atypical antipsychotics used in the treatment of serious mental illness integrated with Proteus sensors.

The companies will together on the development of next generation product features and sensor capabilities to expand the potential of digital medicine offerings.

Andrew Thompson, President and CEO of Proteus Digital Health said this dedication to a wide inter-operable platform is the main reason his company expanding its collaboration with Otsuka in mental health. “This expanded collaboration is a great opportunity to bring novel digital medicine solutions to mental health patients,” he said.

Read more How Smart Pills Could Revolutionize Healthcare


ABILIFY MYCITE® is FDA-approved aripiprazole tablets with sensor to track drug ingestion, for the treatment of schizophrenia, bipolar disorder, acute manic and mixed episodes and maintenance therapy, and the adjunctive treatment of major depressive disorder. ABILIFY MYCITE has not been shown to improve patient compliance or for use in modifying aripiprazole dosage. It should not be used in “real-time” or during an emergency, because detection may be delayed or not occur. The ABILIFY MYCITE System provides an objective summary of drug ingestion over time, to help enhance collaboration with healthcare providers who treat patients with certain serious mental illnesses. Only functions related to tracking drug ingestion have been evaluated or approved by FDA.

Previous articleScientists Create New Stretchable, Wearable Sensor from Chewing Gum
Next articleDialog Semiconductor Agrees to Strengthen Partnership with Apple Through Technology Licensing Agreement
Johanna Mischke
Johanna Mischke () is Editor-in-Chief at WT | Wearable Technologies – the pioneer and worldwide leading innovation and market development platform for technologies worn close to the body, on the body or even in the body. Besides being an expert for wearables and their broader ecosystem she is experienced in the startup world and international marketing. Johanna can be reached at j.mischke(at)